natgillin/translations-raw huggingface dataset:
The most commonly reported (≥ 10%) drug-related adverse reactions in both settings were mild nausea, vomiting, diarrhoea, abdominal pain, fatigue, myalgia, muscle cramps and rash.
Najčešće zabilježene nuspojave (10%), u obje bolesti koje su povezane s primjenom lijeka, bile su blaga mučnina, povraćanje, proljev, bol u trbuhu, umor, bol u mišićima, grčevi u mišićima i osip.
The most commonly reported (≥ 10%) drug-related adverse reactions in both settings were mild nausea, vomiting, diarrhoea, abdominal pain, fatigue, myalgia, muscle cramps and rash.
Najčešće zabilježene nuspojave (10%), u obje bolesti, koje su povezane s primjenom lijeka, bile su blaga mučnina, povraćanje, proljev, bol u trbuhu, umor, bol u mišićima, grčevi u mišićima i osip.
The most commonly reported (≥ 10%) drug-related adverse reactions in both settings were mild nausea, vomiting, diarrhoea, abdominal pain, fatigue, myalgia, muscle cramps and rash.
Najčešće zabilježene nuspojave(10%) koje su povezane s primjenom lijeka, bile su u obje situacije blaga mučnina, povraćanje, proljev, bol u trbuhu, umor, bol u mišićima, grčevi u mišićima i osip.
The most commonly reported (≥ 10%) medicinal product-related adverse reactions in both settings were mild nausea, vomiting, diarrhoea, abdominal pain, fatigue, myalgia, muscle cramps and rash.
Najčešće zabilježene nuspojave (≥10%) koje su povezane s primjenom lijeka, bile su u obje situacije blaga mučnina, povraćanje, proljev, bol u trbuhu, umor, bol u mišićima, grčevi u mišićima i osip.
The most commonly reported ( 10%) drug- related adverse reactions in both settings were mild nausea, vomiting, diarrhoea, abdominal pain, fatigue, myalgia, muscle cramps and rash.
Najčešće zabilježene nuspojave (10%) koje su povezane s primjenom lijeka, bile su u obje situacije blaga mučnina, povraćanje, proljev, bol u trbuhu, umor, bol u mišićima, grčevi u mišićima i osip.
The most commonly reported adverse drug reaction occurring in  10% of patients is headache.
Najčešće zabilježena nuspojava, koja se javila u  10% bolesnika, bila je glavobolja.
The most commonly reported Adverse Drug Reactions (ADRs) (occurring in ≥ 5% of patients treated with tocilizumab monotherapy or in combination with DMARDs) were upper respiratory tract infections, nasopharyngitis, headache, hypertension and increased ALT.
Najčešće prijavljene nuspojave na lijek (pojavljuju se u ≥ 5% bolesnika liječenih tocilizumabom u monoterapiji ili u kombinaciji s DMARD-ovima) bile su infekcije gornjeg dišnog sustava, nazofaringitis, glavobolja, hipertenzija i povišene vrijednosti ALT-a.
The most commonly reported adverse drug reactions (ADRs) were diarrhoea (42%) and rash (24%).
Najčešće prijavljivane nuspojave bile su proljev (42%) i osip (24%).
The most commonly reported adverse drug reactions are nasopharyngitis (14.0%), headache (13.6%) and anaemia (13.2%, see section 4.4).
Najčešće prijavljene nuspojave bile su nazofaringitis (14,0%), glavobolja (13,6%) i anemija (13,2%, vidjeti dio 4.4).
The most commonly reported adverse drug reactions during primary hypercholesterolaemia and mixed dyslipidaemia pivotal trials, at the recommended doses, were nasopharyngitis (4.8%), upper respiratory tract infection (3.2%), back pain (3.1%), arthralgia (2.2%), influenza (2.3%), and nausea (2.1%).
Najčešće prijavljivane nuspojave na lijek, primijenjen u preporučenoj dozi tijekom ključnih ispitivanja učinka lijeka na primarnu hiperkolesterolemiju i miješanu dislipidemiju, bile su: nazofaringitis (4,8%), infekcija gornjih dišnih puteva (3,2%), bol u leđima (3,1%), artralgija (2,2%), gripa (2,3%) i mučnina (2,1%).
The most commonly reported adverse drug reactions have been diarrhoea, rash, nausea, hypertension, and headache.
Najčešće prijavljene nuspojave lijeka bile su proljev, osip, mučnina, hipertenzija i glavobolja.
The most commonly reported adverse event is abdominal pain, occurring in more than 10% of patients in clinical trials.
Najčešće prijavljene nuspojave bile su bol u trbuhu, opažene u više od 10% bolesnica u kliničkim ispitivanjima.
The most commonly reported adverse reaction during treatment is diarrhoea.
Najčešće prijavljena nuspojava tijekom liječenja je proljev.
The most commonly reported adverse reaction leading to discontinuation in patients treated with Plegridy 125 micrograms subcutaneously every 2 weeks was influenza-like illness (<1%).
Najčešće prijavljena nuspojava koja je dovela do prekida liječenja u bolesnika liječenih Plegridyjem u dozi od 125 mikrograma supkutanom injekcijom svaka dva tjedna, je bila bolest nalik gripi (<1%).
The most commonly reported adverse reaction with Cerdelga is diarrhoea, in approximately 6% of the patients.
Najčešće prijavljivana nuspojava na lijek Cerdelga je proljev, kod približno 6% bolesnika.
The most commonly reported adverse reactions (occurring in >10% of patients) are thrombocytopaenia, anaemia, pyrexia, hypertension, hypokalaemia, hypophosphataemia, urinary tract infection, hypercholesterolaemia, hyperglycaemia, hypertriglyceridaemia, abdominal pain, lymphocoele, peripheral oedema, arthralgia, acne, diarrhoea, pain, constipation, nausea, headache, increased blood creatinine, and increased blood lactate dehydrogenase (LDH).
Najčešće prijavljene nuspojave (javljaju se u >10% bolesnika) su trombocitopenija, anemija, pireksija, hipertenzija, hipokalemija, hipofosfatemija, infekcije mokraćnih puteva, hiperkolesterolemija, hiperglikemija, hipertrigliceridemija, bol u abdomenu, limfokela, periferni edem, artralgija, akne, proljev, bol, konstipacija, mučnina, glavobolja, povišena razina kreatinina u krvi, povišena razina laktat dehidrogenaze (LDH) u krvi.
The most commonly reported adverse reactions (≥ 20%) among patients treated with both belatacept- based regimens (MI and LI) up to Year 3 are diarrhoea, anaemia, urinary tract infection, peripheral oedema, constipation, hypertension, pyrexia, nausea, graft dysfunction, cough, vomiting, leukopenia, hypophosphataemia, and headache.
Najčešće nuspojave (≥ 20%) zabilježene u bolesnika liječenih s dva režima primjene belatacepta (MI i LI) tijekom 3 godine bile su proljev, anemija, infekcija mokraćnih puteva, periferni edemi, konstipacija, hipertenzija, pireksija, mučnina, poremećaj funkcije presatka, kašalj, povraćanje, leukopenija, hipofosfatemija i glavobolja.
The most commonly reported adverse reactions (≥5%) were: nausea, hypersensitivity reactions, infusion site reactions, and headache.
Najčešće prijavljivane nuspojave (≥5%) bile su: mučnina, reakcije preosjetljivosti, reakcije na mjestu infuzije i glavobolja.
The most commonly reported adverse reactions are bleedings occurring in total in approximately 14 % of patients treated short-term for elective hip or knee replacement surgery, 16,6 % in patients with atrial fibrillation treated long-term for the prevention of stroke and SEE, and in 14,4 % of patients treated for DVT/PE.
Najčešće prijavljene nuspojave su krvarenja koja su se pojavila u ukupno oko 14 % bolesnika liječenih kratkotrajno zbog elektivnog kirurškog zahvata ugradnje endoproteze kuka ili koljena, 16,6 % u bolesnika s fibirilacijom atrija dugotrajno liječenih radi prevencije moždanog udara i SE-a, kao i 14,4% bolesnika liječenih zbog DVT/PE-a.
The most commonly reported adverse reactions are bleedings occurring in total in approximately 14 % of patients; the frequency of major bleeds (including wound site bleedings) is less than 2 %.
Najčešće prijavljene nuspojave su krvarenja koja su se pojavila u ukupno oko 14 % bolesnika; učestalost velikih krvarenja (uključujući krvarenja iz rane) je manja od 2%.
The most commonly reported adverse reactions are headache, diarrhoea, nausea and vomiting, jaw pain, myalgia, pain in extremity, arthralgia, and flushing.
Najčešće zabilježene nuspojave su glavobolja, proljev, mučnina i povraćanje, bol u čeljusti, mialgija, bol u ekstremitetima, artralgija i crvenilo uz osjećaj vrućine.
The most commonly reported adverse reactions are nausea and headache, occurring in approximately 11%, and 6% of patients, respectively.
Najčešće prijavljene nuspojave su mučnina i glavobolja, koje se javljaju u približno 11%, odnosno 6% bolesnika.
The most commonly reported adverse reactions are upper gastrointestinal adverse reactions including abdominal pain, dyspepsia, oesophageal ulcer, dysphagia, abdominal distension and acid regurgitation (> 1 %).
Najčešće prijavljene nuspojave su nuspojave u gornjem dijelu gastrointestinalnog trakta koje uključuju bol u abdomenu, dispepsiju, ulkus jednjaka, disfagiju, abdominalnu distenziju i regurgitaciju želučane kiseline (> 1%).
The most commonly reported adverse reactions during treatment with VELCADE are nausea, diarrhoea, constipation, vomiting, fatigue, pyrexia, thrombocytopenia, anaemia, neutropenia, peripheral neuropathy (including sensory), headache, paraesthesia, decreased appetite, dyspnoea, rash, herpes zoster and myalgia.
Najčešće prijavljene nuspojave tijekom liječenja VELCADEom jesu mučnina, proljev, zatvor, povraćanje, umor, pireksija, trombocitopenija, anemija, neutropenija, periferna neuropatija (uključujući senzornu), glavobolja, parestezija, smanjeni apetit, dispneja, osip, herpes zoster i mialgija.
The most commonly reported adverse reactions following Twinrix Adult administration with the standard 0, 1, 6 month schedule are pain and redness occurring in a per dose frequency of 37.6% and 17.0% respectively.
Najčešće prijavljene nuspojave nakon primjene cjepiva Twinrix Adult pri standardnoj shemi od 0, 1, i 6 mjeseci su bol i crvenilo, koje se javljaju s učestalošću po dozi od 37,6% odnosno 17,0%.
The most commonly reported adverse reactions following Twinrix Adult administration with the standard 0, 1, 6 month schedule are pain and redness occurring in a per dose frequency of 37.6% and 17.0% respectively.
Najčešće prijavljene nuspojave nakon primjene cjepiva Twinrix Adult pri standardnoj shemi od 0, 1, i 6 mjeseci su bol i crvenilo,koje se javljaju s učestalošću po dozi od 37,6% odnosno 17,0%.
The most commonly reported adverse reactions following Twinrix Paediatric administration are pain and redness occurring in a per dose frequency of 28.5% and 11.5% respectively.
Najčešće prijavljene nuspojave nakon primjene cjepiva Twinrix Paediatric su bol i crvenilo, koje se javljaju s učestalošću po dozi od 28,5% odnosno 11,5%.
The most commonly reported adverse reactions for tacrolimus (occurring in >10% of patients) are tremor, renal impairment, hyperglycaemic conditions, diabetes mellitus, hyperkalaemia, infections, hypertension and insomnia.
Najčešće prijavljene nuspojave na takrolimus (javljaju se u > 10% bolesnika) uključuju tremor, oštećenje bubrega, hiperglikemiiska stanja, šećernu bolest, hiperkalijemiju, infekcije, hipertenziju i nesanicu.
The most commonly reported adverse reactions in clinical studies among sildenafil treated patients were headache, flushing, dyspepsia nasal congestion, dizziness, nausea, hot flush, visual disturbance, cyanopsia and vision blurred.
Najčešće zabilježene nuspojave u kliničkim ispitivanjima u bolesnika liječenih sildenafilom bile su glavobolja, naleti crvenila, dispepsija, nazalna kongestija, omaglica, mučnina, navale vrućine, poremećaji vida, cijanopsija i zamagljen vid.
The most commonly reported adverse reactions in clinical studies among sildenafil treated patients were headache, flushing, dyspepsia, nasal congestion, dizziness, nausea, hot flush, visual disturbance, cyanopsia and. vision blurred.
Najčešće zabilježene nuspojave u kliničkim ispitivanjima u bolesnika liječenih sildenafilom bile su glavobolja, naleti crvenila, dispepsija, nazalna kongestija, omaglica, mučnina, navale vrućine, poremećaji vida, cijanopsija i zamagljen vid.
The most commonly reported adverse reactions in clinical studies have been blood and lymphatic system disorders including anaemia (45.7%), neutropenia (45.3%) and thrombocytopenia (27%); in general disorders and administration site conditions including fatigue (28.3%), pyrexia (21%) and oedema peripheral (13%); and in infections and infestations including pneumonia (10.7%).
U kliničkim ispitivanjima, najčešće zabilježene nuspojave bile su poremećaji krvi i limfnog sustava koji su uključivali anemiju (45,7%), neutropeniju (45,3%) i trombocitopeniju (27%); opći poremećaji i reakcije na mjestu primjene koji su uključivali umor (28,3%), pireksiju (21%) i periferne edeme (13%); i infekcije i infestacije koje su uključivali pneumoniju (10,7%).
The most commonly reported adverse reactions in dialysis-dependent chronic kidney disease (CKD 5D) patients during treatment were discoloured faeces and diarrhoea occurring in 18% and 13% of patients, respectively.
Najčešće prijavljene nuspojave tijekom liječenja bolesnika s kroničnom bolesti bubrega na dijalizi (KBB 5D) bile su promjena boje fecesa koja se javila u 18 %, i proljev koji se javio u 13 % bolesnika.
The most commonly reported adverse reactions in patients receiving rivaroxaban were bleedings (see section 4.4. and ‘Description of selected adverse reactions’ below).
Najčešće prijavljene nuspojave u bolesnika koji su primali rivaroksaban bile su krvarenja (vidjeti dio 4.4 i 'Opis odabranih nuspojava' niže).
The most commonly reported adverse reactions in patients treated with FORSTEO are nausea, pain in limb, headache and dizziness.
Najčešće prijavljene nuspojave u bolesnika liječenih lijekom FORSTEO su mučnina, bol u udovima, glavobolja i omaglica.
The most commonly reported adverse reactions in Phase III clinical studies have been gastrointestinal (GI) disorders including diarrhoea (15.7%) and nausea (13.9%).
Najčešće prijavljena nuspojava u fazi III kliničkih ispitivanja bili su poremećaji probavnog sustava, uključujući proljev (15,7%) i mučninu (13,9%).
The most commonly reported adverse reactions in placebo-controlled trials are akathisia and nausea each occurring in more than 3 % of patients treated with oral aripiprazole.
Najčešće prijavljene nuspojave u placebom kontroliranim ispitivanjima su akatizija i mučnina, od kojih se svaka javlja u više od 3 % bolesnika liječenih oralnim aripiprazolom.
The most commonly reported adverse reactions in placebo-controlled trials are nausea, dizziness and somnolence each occurring in more than 3 % of patients treated with aripiprazole solution for injection.
Najčešće prijavljene nuspojave u placebom kontroliranim ispitivanjima su mučnina, omaglica i somnolencija i svaka javlja u više od 3 % bolesnika liječenih aripiprazol otopinom za injekciju.
The most commonly reported adverse reactions in the main safety, active-controlled clinical study with TOBI Podhaler versus tobramycin nebuliser solution in cystic fibrosis patients with P. aeruginosa infection were cough, productive cough, pyrexia, dyspnoea, oropharyngeal pain, dysphonia and haemoptysis.
Najčešće zabilježene nuspojave u glavnom aktivno kontroliranom kliničkom ispitivanju sigurnosti TOBI Podhalera u usporedbi s tobramicin otopinom za nebulizator u bolesnika s cističnom fibrozom i infekcijom s P. aeruginosa bile su kašalj, produktivan kašalj, pireksija, dispneja, orofaringealna bol, disfonija i hemoptiza.
The most commonly reported adverse reactions leading to discontinuation (incidence >1%) in patients treated with Tecfidera were flushing (3%) and gastrointestinal events (4%).
Najčešće prijavljene nuspojave koje su dovele do prekida (incidencija >1%) u bolesnika liječenih Tecfiderom su crvenilo uz osjećaj vrućine (3%), i gastrointestinalne smetnje (4%).
The most commonly reported adverse reactions occurring in  10% of patients with acromegaly treated with pegvisomant during the clinical trials were headache 25%, arthralgia 16% and diarrhoea 13%.
Najčešće zabilježene nuspojave nastale u ≥10% bolesnika s akromegalijom liječenom pegvisomantom tijekom kliničkih ispitivanja bile su glavobolja u 25%, artralgija u 16% i proljev u 13%.
The most commonly reported adverse reactions of Docetaxel alone are: decrease in the number of red blood cells or white blood cells, alopecia, nausea, vomiting, sores in the mouth, diarrhoea and tiredness.
Najčešće prijavljivane nuspojave lijeka Docetaxel kada se primjenjuje sam su: pad broja crvenih ili bijelih krvnih stanica, gubitak kose, mučnina, povraćanje, ranice u ustima, proljev i umor.
The most commonly reported adverse reactions of docetaxel alone are: neutropenia (which was reversible and not cumulative; the median day to nadir was 7 days and the median duration of severe neutropenia (<500 cells/mm3) was 7 days), anaemia, alopecia, nausea, vomiting, stomatitis, diarrhoea and asthenia.
Najčešće prijavljene nuspojave samog docetaksela su: neutropenija (koja je bila reverzibilna i nije bila kumulativna; medijan javljanja najnižih vrijednosti je bio 7 dana, a medijan trajanja teške neutropenije (<500 stanica/mm3 ) je bio 7 dana), anemija, alopecija, mučnina, povraćanje, stomatitis, proljev i astenija.
The most commonly reported adverse reactions of docetaxel alone are: neutropenia (which was reversible and not cumulative; the median day to nadir was 7 days and the median duration of severe neutropenia (<500 cells/mm3) was 7 days), anaemia, alopecia, nausea, vomiting, stomatitis, diarrhoea and asthenia.
Najčešće prijavljene nuspojave samog docetaksela su: neutropenija (koja je bila reverzibilna i nije bila kumulativna; medijan javljanja najnižih vrijednosti je bio 7 dana, a medijan trajanja teške neutropenije (500 stanica/mm3) je bio 7 dana), anemija, alopecija, mučnina, povraćanje, stomatitis, proljev i astenija.
The most commonly reported adverse reactions of Docetaxel Winthrop alone are: decrease in the number of red blood cells or white blood cells, alopecia, nausea, vomiting, sores in the mouth, diarrhoea and tiredness.
Najčešće prijavljivane nuspojave Docetaxel Winthrop kada se primjenjuje sam su: pad broja crvenih ili bijelih krvnih stanica, gubitak kose, mučnina, povraćanje, ranice u ustima, proljev i umor.
The most commonly reported adverse reactions of severe intensity were diarrhoea (4 subjects, 14%), vomiting (3 patients, 10%), and abdominal distension and ALT increased (2 subjects each, 7%).
Najčešće prijavljivane nuspojave jakog intenziteta bile su proljev (4 bolesnika, 14%), povraćanje (3 bolesnika, 10%) te abdominalna distenzija i povišene vrijednosti ALT (za svaku nuspojavu 2 ispitanika, 7%).
The most commonly reported adverse reactions were abdominal pain and distension (49%), respiratory tract infections (28%), nausea (27%), injection site reactions (21%), headache (17%), vomiting (14%) and oedema peripheral (10%).
Najčešće prijavljene nuspojave bile su bol i napetost u trbuhu (49%), infekcije dišnog sustava (28%), mučnina (27%), reakcije na mjestu primjene (21%), glavobolja (17%), povraćanje (14%) i periferni edem (10%).
The most commonly reported and/or clinically relevant treatment-related adverse drug reactions (ADRs) were gastrointestinal disorders (especially diarrhoea, nausea, vomiting, abdominal pain, stomatitis), hand-foot syndrome (palmar-plantar erythrodysesthesia), fatigue, asthenia, anorexia, cardiotoxicity, increased renal dysfunction on those with preexisting compromised renal function, and thrombosis/embolism.
Najčešće prijavljivane i/ili klinički značajne nuspojave povezane s liječenjem su poremećaji probavnog sustava (naročito proljev, mučnina, povraćanje, bol u abdomenu, stomatitis), sindrom šaka- stopalo (palmarno-plantarna eritrodizestezija), umor, astenija, anoreksija, kardiotoksičnost, pogoršanje bubrežne funkcije u bolesnika s prethodnim oštećenjem bubrežne funkcije i tromboza/embolija.
The most commonly reported bleedings (≥4 %) were epistaxis (5.9 %) and gastrointestinal tract haemorrhage (4.2 %).
Najčešće prijavljena krvarenja (≥4%) bila su epistaksa (5,9%) i krvarenje iz gastrointestinalnog trakta (4,2%).
The most commonly reported grade 3/4 laboratory abnormalities with an incidence of ≥5% occurring in patients treated with Odomzo 200 mg were lipase increase and blood CK increase (Table 3).
Najčešće prijavljena odstupanja u nalazima laboratorijskih pretraga stupnja 3/4 s incidencijom od ≥ 5% koja su se javila u bolesnika liječenih Odomzom 200 mg bila su povišena lipaza i povišeni CPK u krvi (Tablica 3).
The most commonly reported reactions are listed in section 4.8. Generally these symptoms are mild to moderate, however, in some patients they may be severe in intensity.
Najčešće prijavljene nuspojave navedene su u dijelu 4.8. Općenito su ti simptomi blagi do umjereni, međutim u nekih bolesnica mogu biti teški po intenzitetu.
The most commonly reported reactions are listed in section 4.8. Generally these symptoms are mild to moderate, however, in some patients they may be severe in intensity.
Najčešće prijavljene nuspojave navedene su u dijelu 4.8. Općenito su ti simptomi blagi do umjereni, međutim u nekih bolesnika mogu biti teški po intenzitetu.
The most commonly reported reactions are listed in section 4.8. Generally these symptoms are mild to moderate, however, in some patients they may be severe in intensity.
Najčešće prijavljene nuspojave navedene su u dijelu 4.8. U načelu su ti simptomi blagi do umjereni, ali u nekih bolesnika mogu biti i teški.
The most commonly reported serious adverse reaction was cellulitis (1.1%, 11/976).
Najčešće prijavljivana ozbiljna nuspojava bila je celulitis (1,1%; 11/976).
The most commonly reported side effects are gastrointestinal disorders (such as diarrhoea, nausea), nervous system disorders (such as dizziness, headache, somnolence) and fatigue.
Najčešće prijavljivane nuspojave bile su poremećaji probavnog sustava (kao što su proljev, mučnina), poremećaji živčanog sustava (kao što su omaglica, glavobolja, pospanost) i umor.
The most commonly reported side effects are local injection site reactions such as erythema, swelling and pruritus that are usually transient in nature and mild in intensity.
Najčešće prijave o nuspojavama su lokalne reakcije na mjestu injiciranja kao što su eritem, oticanje i pruritus, a obično su prolazne i blagog intenziteta.
The most commonly reported side effects during clinical study experience with Esbriet were nausea (feeling sick), rash, fatigue, diarrhoea, dyspepsia (heartburn), anorexia (loss of appetite), headache and photosensitivity reaction (sunburn-like reactions following exposure to light).
Najčešće prijavljene nuspojave koje su se pojavile tijekom kliničkog ispitivanja s lijekom Esbriet su mučnina (osjećaj slabosti), osip, iscrpljenost, proljev, dispepsija (žgaravica), anoreksija (gubitak apetita), glavobolja i fotoosjetljiva reakcija (reakcije poput opekline sunca nakon izlaganja svjetlu).
The most commonly reported side effects with Envarsus (seen in more than 1 patient in 10) are tremor (shaking), headache, nausea (feeling sick), diarrhoea, kidney problems, hyperglycaemia (raised blood glucose levels), diabetes, hyperkalaemia (raised blood potassium levels), hypertension (high blood pressure) and insomnia (difficulty sleeping).
Najčešće zabilježene nuspojave uzimanja Envarsusa (zabilježeno u više od 1 na 10 bolesnika) su drhtavica (drhtanje), glavobolja, mučnina (osjećaj mučnine), proljev, problemi s bubrezima, hiperglikemija (povišena razina glukoze u krvi), dijabetes, hiperkalemija (povišena razina kalija u krvi), hipertenzija (visoki krvni tlak) i nesanica (poteškoće sa spavanjem).
The most commonly reported side effects with Revestive were abdominal pain and distension (aching and swollen stomach, 49%), respiratory tract infections (infections of the throat, sinuses, airways or lungs, 28%), nausea (feeling sick, 27%), reddening, pain or swelling at the site of the injection (21%), headache (17%), vomiting (14%) and peripheral oedema (swelling of hands and/or feet, 10%).
Najčešće prijavljene nuspojave lijeka Revestive bile su abdominalna bol i distenzija (bolan i otečen želudac, 49%), infekcije dišnog sustava (infekcije grla, sinusa, dišnih putova ili pluća, 28%), mučnina (osjećaj slabosti, 27%), crvenilo, bol ili oticanje na mjestu primjene (21%), glavobolja (17%), povraćanje (14%) i periferni edem (oticanje ruku i/ili stopala, 10%).